AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders

Current Opinion in Investigational Drugs

Volumn 9, Issue 7, 2008, Pages 800-811

  Geerts, H ^a  

^a In Silico Biosciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY DEPENDENT NEUROPROTECTIVE FACTOR; ADNF 9; AFX 64; AL 108; AL 208; AL 209; ALCOHOL; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BRAIN PROTEIN; BUTHIONINE SULFOXIMINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE; GALANTAMINE; GLUCOSE; GLUTATHIONE; HOMOTAURINE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MEMANTINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAP FRAGMENT; NEUROPROTECTIVE AGENT; NP 12; PACLITAXEL; PRESENILIN 1; RIVASTIGMINE; SN 2127; TACRINE; TARENFLURBIL; TAU PROTEIN; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART MUSCLE ISCHEMIA; HUMAN; ISOTOPE LABELING; LOW DRUG DOSE; NEUROPROTECTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; PATENTS AS TOPIC; SCHIZOPHRENIA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46749144675     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. 277841 Alzheimer's disease: The amyloid cascade hypothesis. Hardy JA, Higgins GA SCIENCE 1992 256 5054 184-185
2. 433542 Selective loss of central cholinergic neurons in Alzheimer's disease. Davies P, Maloney AJ LANCET 1976 2 8000 1403-1403
3. 510192 The relationship between amyloid and tau. Hardy J J MOL NEUROSCI 2003 20 2 203-206
4. 554615 Drug development. Allon Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2004 August 16
5. 555738 Institute for the Study of Aging awards second founder's program investment in new biotechnology company Allon Therapeutics Inc PRESS RELEASE 2003 January 29
6. 589151 Allon Therapeutics compounds show potential to treat eye disease. Allon Therapeutics Inc PRESS RELEASE 2005 March 08
7. 678561 Neuropharma presents latest advances at the International Congress on Alzheimer's disease. Neuropharma SA PRESS RELEASE 2006 July 14
8. 686394 Allon begins enrolment for AL-208 phase II clinical trial. Allon Therapeutics Inc PRESS RELEASE 2006 June 02
9. 757286 Allon drug selected for clinical trial in the treatment of cognitive impairment in schizophrenia. Allon Therapeutics Inc PRESS RELEASE 2007 January 08
10. 759314 Allon Therapeutics website. Allon Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2007 January 22
11. 760962 Allon confirms progress in AL-208 phase II clinical trial. Allon Therapeutics Inc PRESS RELEASE 2007 January 22
12. 761020 Michael J. Fox Foundation funds Allon to evaluate AL-108 for Parkinson's disease Allon Therapeutics Inc PRESS RELEASE 2007 January 24
13. 761244 (R)-flurbiprofen - an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. Geerts H IDRUGS 2007 10 2 121-133
14. 764540 NCT00404014: Study to evaluate safety, tolerability and effect of AL208 on mild cognitive impairment following coronary artery bypass graft surgery. CLINICALTRIALS.GOV 2007
15. 770072 NCT00422981: Safety, tolerability and efficacy study to evaluate subjects with mild cognitive impairment. CLINICALTRIALS. GOV 2007 February 28
16. 774210 Allon product AL-108 successful in phase Ib clinical trial. Allon Therapeutics Inc PRESS RELEASE 2007 March 07
17. 829738 Allon begins phase II schizophrenia-related CI trial of AL-108. Allon Therapeutics Inc PRESS RELEASE 2007 September 12
18. 837767 Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I J PHARMACOL EXP THER 2007 323 2 438-449
19. 842006 New frontiers in CNS drug discovery, Harlow, UK, 18 October 2007. Norman P IDDB MEETING REPORT 2007 October 18
20. 863349 NCT00574132: Bapineuzumab in patients with mild to moderate Alzheimer's disease. CLINICALTRIALS.GOV 2007 December 18
21. 866607 Allon begins pharmacokinetics study of cognitive impairment drugs. Allon Therapeutics Inc PRESS RELEASE 2008 January 10
22. 873777 Activity-dependent neuroprotective protein: From gene to drug candidate. Gozes I PHARMACOL THER 2007 114 2 146-154
23. 873779 Neurotrophic effects of the peptide NAP: A novel neuroprotective drug candidate. Gozes I, Spivak-Pohis I CURR ALZHEIMER RES 2006 3 3 197-199
24. 873781 NAP: Research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y et al CNS DRUG REV 2005 11 4 353-368
25. 873784 The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Gozes I, Zaltzman R, Hauser J, Brenneman DE, Shohami E, Hill JM CURR ALZHEIMER RES 2005 2 2 149-153
26. 876814 Philadelphia: European trial of Alzhemed ends, marketing morphs to supplement. McCaffrey P, Strobel G INTERNET SITE 2007 November 19
27. 878233 Allon expands phase I AL-108 and AL-208 trial to include AD patients. Allon Therapeutics Inc PRESS RELEASE 2008 February 20
28. 880416 Allon's AL-108 improves memory in phase IIa cognitive disorder trial. Allon Therapeutics Inc PRESS RELEASE 2008 February 26
29. 892204 Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Andrieux A, Salin P, Schweitzer A, Begou M, Pachoud B, Brun P, Gory-Faure S, Kujala P, Suaud-Chagny MF, Hofle G, Job D BIOL PSYCHIATRY 2006 60 11 1224-1230
30. 892205 A novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities. Blat D, Weiner L, Youdim MB, Fridkin M J MED CHEM 2008 51 1 126-134
31. 892207 A femtomolar-acting neuroprotective peptide. Brenneman DE, Gozes I J CLIN INVEST 1996 97 10 2299-2307
32. 892208 Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE et al J NEUROCHEM 1999 72 3 1283-1293
33. 892209 NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Busciglio J, Pelsman A, Helguera P, Ashur-Fabian O, Pinhasov A, Brenneman DE, Gozes I CURR PHARM DESIGN 2007 13 11 1091-1098
34. 892211 Peptide neuroprotection through specific interaction with brain tubulin. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I J NEUROCHEM 2006 98 3 973-984
35. 892213 Expression of activity-dependent neuroprotective protein in the brain of adult rats. Gennet N, Herden C, Bubb VJ, Quinn JP, Kipar A HISTOL HISTOPATHOL 2008 23 3 309-317
36. 892214 Activity-dependent neurotrophic factor: Intranasal administration of femtomolar-acting peptides improve performance in a water maze. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE J PHARMACOL EXP THER 2000 293 3 1091-1098
37. 892281 NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Gozes I, Divinski I CURR ALZHEIMER RES 2007 4 5 507-509
38. 892282 Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. Holtser-Cochav M, Divinski I, Gozes I J MOL NEUROSCI 2006 28 3 303-307
39. 892283 The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Lagreze WA, Pielen A, Steingart R, Schlunck G, Hofmann HD, Gozes I, Kirsch M INVEST OPHTHALMOL VIS SCI 2005 46 3 933-938
40. 892285 Facilitation of performance in a working memory task with rTMS stimulation of the precuneus: Frequency- and time-dependent effects. Luber B, Kinnunen LH, Rakitin BC, Ellsasser R, Stern Y, Lisanby SH BRAIN RES 2007 1128 1 120-129
41. 892294 Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Mandel S, Rechavi G, Gozes I DEV BIOL 2007 303 2 814-824
42. 892300 Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS J MOL NEUROSCI 2007 31 2 165-170
43. 892301 A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O et al J PHARMACOL EXP THER 2008 325 1 146-153
44. 892307 Nicotine improves delayed recognition in schizophrenic patients. Myers CS, Robles O, Kakoyannis AN, Sherr JD, Avila MT, Blaxton TA, Thaker GK PSYCHOPHARMACOLOGY 2004 174 3 334-340
45. 892310 The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T et al AM J PSYCHIATRY 2008 165 2 203-213
46. 892314 β-Amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC BRAIN 2007 130 11 2837-2844
47. 892315 NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Quintana FJ, Zaltzman R, Fernandez-Montesinos R, Herrera JL, Gozes I, Cohen IR, Pozo D ANN NY ACAD SCI 2006 1070 500-506
48. 892316 Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine. Riepe MW, Adler G, Ibach B, Weinkauf B, Tracik F, Gunay I DEMENT GERIATR COGN DISORD 2007 23 5 301-306
49. 892320 NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I J PHARMACOL EXP THER 2006 319 1 332-339
50. 892323 Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Tarkowski E, Liljeroth AM, Minthon L, Tarkowski A, Wallin A, Blennow K BRAIN RES BULL 2003 61 3 255-260
51. 892324 Glutamatergic mechanisms in schizophrenia. Tsai G, Coyle JT ANNU REV PHARMACOL TOXICOL 2002 42 165-179
52. 892325 PolyADP-ribosylation is involved in neurotrophic activity. Visochek L, Steingart RA, Vulih-Shultzman I, Klein R, Priel E, Gozes I, Cohen-Armon M J NEUROSCI 2005 25 32 7420-7428
53. 892327 Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM et al PROC NATL ACAD SCI USA 2005 102 1 227-231
54. 905692 Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. Smith-Swintosky VL, Gozes I, Brenneman DE, D'Andrea MR, Plata-Salaman CR J MOL NEUROSCI 2005 25 3 225-238
55. 906230 Allon therapeutics releases first quarter operating results. Allon Therapeutics Inc PRESS RELEASE 2008 May 15
56. 907996 The epidemiology of the dementias: An update. Qiu C, De Ronchi D, Fratiglioni L CURR OPIN PSYCHIATRY 2007 20 4 380-385
57. 907997 Beyond amyloid: The next generation of Alzheimer's disease therapeutics. Seabrook GR, Ray WJ, Shearman M, Hutton M MOL INTERVENT 2007 7 5 261-270
58. 907998 Therapeutic perspectives in Alzheimer's disease. Tschape JA, Hartmann T CNS DRUGS 2006 1 1 119-127
59. 908000 Immunotherapy as treatment for Alzheimer's disease. Hawkes CA, McLaurin J EXPERT REV NEUROTHERAPEUTICS 2007 7 11 1535-1548
60. 908001 Neuroprotection and neurodegenerative diseases: From biology to clinical practice. Akwa Y, Allain H, Bentue-Ferrer D, Berr C, Bordet R, Geerts H, Nieoullon A, Onteniente B, Vercelletto M ALZHEIMER DIS ASSOC DISORD 2005 19 4 226-239
61. 908002 Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Dejda A, Sokołowska P, Nowak JZ PHARMACOL REP 2005 57 3 307-320
62. 908004 SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl) phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl] ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. Biochemical and pharmacological characterization. Emonds-Alt X, Proietto V, Steinberg R, Oury-Donat F, Vigé X, Vilain P, Naline E, Daoui S, Advenier C, Le Fur G, Maffrand JP et al J PHARMACOL EXP THER 2002 303 3 1171-1179
63. 908005 Neuroprotective effect of the peptides ADNF-9 and NAP on hypoxic-ischemic brain injury in neonatal rats. Kumral A, Yesilirmak DC, Sonmez U, Baskin H, Tugyan K, Yilmaz O, Genc S, Gokmen N, Genc K, Duman N, Ozkan H BRAIN RES 2006 1115 1 169-178
64. 908007 A β immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Schenk DB, Seubert P, Grundman M, Black R NEURODEGEN DIS 2005 2 5 255-260
65. 908008 Glycogen synthase kinase 3: A drug target for CNS therapies. Bhat RV, Budd Haeberlein SL, Avila J J NEUROCHEM 2004 89 6 1313-1317
66. 908009 Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Kowall NW, Kosik KS ANN NEUROL 1987 22 5 639-643
67. 908011 Management of toxicities associated with the administration of taxanes. Markman M EXPERT OPIN DRUG SAFETY 2003 2 2 141-146
68. 908013 Five mouse tubulin isotypes and their regulated expression during development. Lewis SA, Lee MG, Cowan NJ J CELL BIOL 1985 101 3 852-861
69. 908014 A revised nomenclature for the human and rodent α-tubulin gene family. Khodiyar VK, Maltais LJ, Sneddon KM, Smith JR, Shimoyama M, Cabral F, Dumontet C, Dutcher SK, Harvey RJ, Lafanechère L, Murray JM et al GENOMICS 2007 90 2 285-289
70. 1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Navarro- Núñez L, Lozano ML, Rivera J, Corral J, Roldán V, González-Conejero R, Iniesta JA, Montaner J, Vicente V, Martínez C HAEMATOLOGICA 2007 92 4 513-518
71. 908878 NCT00505765: A multicenter study of NAP (AL-108) in schizophrenia. CLINICALTRIALS.GOV 2007 December 26
72. 909346 Product information: AL-108. Allon Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 May 08
73. 909354 Product pipeline: Allon Therapeutics. Allon Therapeutics Inc COMPANY WORLD WIDE WEB SITE 2008 May 08
74. 909459 Product information: Availability of Exubera. Pfizer Inc COMPANY WORLD WIDE WEB SITE 2008 May 08
75. 910515 A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. Beni-Adani L, Gozes I, Cohen Y, Assaf Y, Steingart RA, Brenneman DE, Eizenberg O, Trembolver V, Shohami E J PHARMACOL EXP THER 2001 296 1 57-63
76. 910653 Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer's disease. Francis PT NEURODEGEN DIS 2008 5 3-4 241-243
77. 910662 Tauopathies: Recent insights into old diseases. Delacourte A FOLIA NEUROPATHOL 2005 43 4 244-257
78. 910675 Cognitive outcomes three years after coronary artery bypass surgery: Relation to diffusion-weighted magnetic resonance imaging. Knipp SC, Matatko N, Wilhelm H, Schlamann M, Thielmann M, Lösch C, Diener HC, Jakob H ANN THORAC SURG 2008 85 3 872-879
79. 910678 Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-boc-3-i-butylisoserinoyl)-C-7, 8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, Morazzoni P et al DRUG METAB DISPOS 2006 34 12 2028-2035
80. 910683 One hundred years after the discovery of Alzheimer's disease. A turning point for therapy? Giacobini E, Becker RE J ALZHEIMER DIS 2007 12 1 37-52
81. 910691 STOP proteins. Bosc C, Oenarier E, Andrieux A, Job D CELL STRUCT FUNCT 1999 24 5 393-399
82. 910809 Annual report 2004. Allon Therapeutics Inc ANNUAL REPORT 2004 April 18
83. 918120 Cloning and characterization of the human activity-dependent neuroprotective protein. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, Bassan M, Wollman Y, Eyre HJ, Mulley JC, Brenneman DE, Gozes I J Biol Chem 2001 276 1 708-714.
84. 918129 Pharmacokinetics of the neuroprotective peptide, NAPVSIPQ in serial samples of plasma and CSF after intravenous or intranasal administration. Morimoto BH, de Lannoy I, Liu X, Gien B, Yang Y, Fox A, Tiong J, Gozes I DRUG METAB REV 2006 38 Suppl 2 213-214
85. 918153 Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Zusev M, Gozes I Regul Pept 2004 123 1-3 33-41.
86. 918158 ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. Mandel S, Spivak-Pohis I, Gozes I J Mol Neurosci 2008 35 2 127-141.
87. 918160 Protective peptides that are orally active and mechanistically nonchiral. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I J PHARMACOL EXP THER 2004 309 3 1190-1197
88. 918837 Development status: AL-108 and AL-208. Allon Therapeutics Inc COMPANY COMMUNICATION 2008 June 19